COVID-19: developers of medicines or vaccines to benefit from free scientific advice from the European Medicines Agency

The EMA will provide full fee waivers for scientific advice applications from developers of potential therapeutics or vaccines against the novel coronavirus (COVID-19) with the aim of providing prompt guidance and direction on best study designs to generate robust information.


European Medicines Agency